Explore opportunities

Search by company name (Bolden, Pax, OncoLux, Nabsys), asset id, or title. Each card links to a full dossier with cited evidence.

Loading filters…

Tier Aip_chitinase_ocf203
Chitinase-1 inhibition for pulmonary fibrosis (OCF-203 family)

Chitinase-1 IPF composition with decades of NHLBI P01 support—license diligence on OCF-203.

Brown-origin US11717528B2—sublicense or asset path via Ocean / Elkurt corporate stack.

Entity: Ocean BiomedicalPatents: 1Stage: preclinical to ind
US11717528B2P01HL114501
Open dossier
Tier Aip_ecm_morsels_xm
Lab-grown decellularized ECM morsels (injectable matrix therapy)

Injectable human ECM morsels for HF and IPF—Slater-seeded Brown spinout.

Slater $375K + BBII—large-animal PoP before Heartseed-class Series A.

Entity: XM TherapeuticsPatents: 5Stage: preclinical proof of principle
US20230348859A1WO2022140530A1US8361781B2US11286451B2US12435312B2PMID 39705507
Open dossier
Research synthesis from public sources (NIH RePORTER, ClinicalTrials.gov, PubMed, USPTO, company press). Not investment advice, legal opinion, or clinical guidance. Verify cap tables, license chains, and trial status in data rooms before term sheets.